Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies.
MarketWatch.com - Top Stories, MarketWatch
Fri, 06/10/2022 - 2:40pm
Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies.